{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2026.05.27.26354223v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2026.05.27.26354223v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2026.05.27.26354223v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAbstract\u003C\/h2\u003E\u003Cdiv id=\u0022sec-1\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-4\u0022\u003E\u003Cstrong\u003EBackground\u003C\/strong\u003E The ongoing Bundibugyo virus disease (BDBV) outbreak in Central Africa highlights the absence of approved vaccines specifically targeting BDBV. Whether licensed Zaire ebolavirus (EBOV) vaccines induce cross-reactive immunity against BDBV remains largely unknown.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-2\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-5\u0022\u003E\u003Cstrong\u003EMethods\u003C\/strong\u003E We performed an immunogenicity analysis using serum samples from participants enrolled in the PREVAC randomized clinical trial evaluating licensed Ebola vaccine strategies in West Africa. Samples collected at day 28 (D28) and month 3 (M3) following vaccination with rVSV\u0394G-ZEBOV-GP or Ad26.ZEBOV\/MVA-BN-Filo were assessed using a multiplex Luminex assay against glycoproteins from multiple filoviruses, including EBOV Kikwit, EBOV Mayinga, BDBV, Sudan virus, Reston virus, and Marburg virus.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-6\u0022\u003E\u003Cstrong\u003EResults\u003C\/strong\u003E A total of 179 samples were analysed. Detectable cross-reactive antibody responses against BDBV were observed across vaccine groups, timepoints, and age categories. However, BDBV responses remained substantially lower than homologous EBOV responses. In rVSV recipients, median BDBV responses (net MFI) reached 282 (IQR 164\u2013644) at D28 compared with 1788 (832\u20133311) against the homologous Kikwit antigen. Similar patterns were observed following rVSV booster vaccination and Ad26.ZEBOV\/MVA-BN-Filo vaccination. The heterologous Ad26\/MVA regimen demonstrated increasing BDBV responses between D28 and M3.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-7\u0022\u003E\u003Cstrong\u003EConclusions\u003C\/strong\u003E Licensed EBOV vaccines induced detectable but quantitatively reduced cross-reactive antibody responses against BDBV. Although no direct assessment of vaccine efficacy against BDBV disease was possible, these findings support the plausibility of partial heterologous immunity following EBOV vaccination. In the absence of approved BDBV-specific vaccines, these data support the urgent evaluation of currently available Ebola vaccines during BDBV outbreaks and reinforce the importance of developing broadly protective pan-filovirus vaccines.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-5\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EIntroduction\u003C\/h2\u003E\u003Cp id=\u0022p-20\u0022\u003EThe ongoing outbreak of Ebola virus disease caused by Bundibugyo virus (BDBV) in the Democratic Republic of the Congo (DRC) and Uganda has rapidly escalated as a major global health concern, with 861 reported cases and an estimated case fatality rate of approximately 21% as of May 25, 2026.\u003Csup\u003E\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E\u003C\/sup\u003E On May 16, 2026, the World Health Organization declared the epidemic a Public Health Emergency of International Concern following evidence of sustained transmission across multiple health zones, cross-border spread, and increasing suspected BVBD-associated mortality.\u003Csup\u003E\u003Ca id=\u0022xref-ref-2-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E\u003C\/sup\u003E\u003C\/p\u003E\u003Cp id=\u0022p-21\u0022\u003EBDBV is a relatively understudied ebolavirus species that was responsible for only two previous documented outbreaks since its identification in 2007. In contrast to Zaire ebolavirus (EBOV), no vaccine or specific therapeutics are currently available for the prevention or treatment of BDBV infection, leaving populations at risk without proven medicinal countermeasures in the context of ongoing transmission. Moreover, current diagnostics that can be used in decentralized settings do not detect BDBV strains, thus delaying thus significantly rapid implementation of countermeasures to interrupt transmission chains. Genomic analyses from the current outbreak suggest a zoonotic spillover event and confirm genetic divergence from EBOV strains targeted by licensed vaccines.\u003Csup\u003E\u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E\u003C\/sup\u003E Therefore, whether currently licensed EBOV vaccines may induce cross reactive immunity against BDBV remains debatable. Preclinical data have suggested partial and inconsistent heterologous protection with the rVSV-ZEBOV platform,\u003Csup\u003E\u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E whereas evidence is scarce for the Ad26.ZEBOV\/MVA-BN-Filo regimen.\u003Csup\u003E\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/sup\u003E Finally, immunogenicity data against BDBV in humans are extremely limited.\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003EIn this context, we assessed cross-reactive antibody responses against multiple ebolavirus species, including BDBV, using serum samples from participants enrolled in the PREVAC randomised clinical trial that evaluated the rVSV-ZEBOV (Ervebo\u00ae, MSD), and Ad26.ZEBOV\/MVA-BN-Filo (Zabdeno\u00ae, Mvabea\u00ae, Janssen), vaccine strategies in adults and in children in West Africa,\u003Csup\u003E\u003Ca id=\u0022xref-ref-8-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E\u003C\/sup\u003E to provide urgently needed insights into potential cross-protective immunity.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-6\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EMethods\u003C\/h2\u003E\u003Cp id=\u0022p-23\u0022\u003EPREVAC (Partnership for Research on Ebola Vaccinations) was a multicentre, randomised, placebo-controlled phase 2 trial conducted in Guinea, Liberia, Mali, and Sierra Leone to evaluate the safety and immunogenicity of three Ebola vaccine strategies in healthy adults and children (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT02876328\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2026%2F05%2F28%2F2026.05.27.26354223.atom\u0022\u003ENCT02876328\u003C\/a\u003E). Participants were randomly assigned to receive either Ad26.ZEBOV (0.5\u25a1ml; 5\u25a1\u00d7\u25a110\u003Csup\u003E10\u003C\/sup\u003E viral particles) followed by MVA-BN-Filo (0.5\u25a1ml; 1\u25a1\u00d7\u25a110\u003Csup\u003E8\u003C\/sup\u003E infectious units) 56 days later (the Ad26\u2013MVA group), rVSV\u0394G-ZEBOV-GP (1.0\u25a1ml; 9.4\u25a1\u00d7\u25a110\u003Csup\u003E7\u003C\/sup\u003E plaque-forming units) followed by placebo 56 days later (the rVSV group), and rVSV\u0394G-ZEBOV-GP followed by rVSV\u0394G-ZEBOV-GP 56 days later (the rVSV\u2013booster group), or placebo. Detailed trial methods and primary results have been previously reported.\u003Csup\u003E\u003Ca id=\u0022xref-ref-8-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E\u003C\/sup\u003E\u003C\/p\u003E\u003Cp id=\u0022p-24\u0022\u003EFor this analysis of cross-reactive antibody responses against ebolavirus species, we analysed a subset of available serum samples collected from vaccinated participants at day 28 (D28) and month 3 (M3) post-vaccination corresponding to expected peak time points of vaccine immune responses. Samples were selected on the basis of availability at the biobank from the Institut de Recherche pour le D\u00e9veloppement (IRD, Montpellier, France) laboratory and included both adults and children across vaccine groups (\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/1226825\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/1226825\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/1226825\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003ECharacteristics of the study population included in the study from the PREVAC trial\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-25\u0022\u003ECross-reactive antibody responses were assessed using a multiplex bead-based Luminex assay. Recombinant glycoprotein antigens representing six filoviruses were evaluated, including EBOV Mayinga (MAY), EBOV Kikwit (KIK), BDBV virus (Uganda 2007), Sudan virus (Gulu), Reston virus, and Marburg virus (Musoke 1980). Plasma samples were tested at a working dilution of 1:200 in duplicate. Samples were incubated with antigen-coated beads for 16 hours at 4\u00b0C under agitation and protected from light, followed by sequential incubation with biotinylated mouse anti-human antibodies and streptavidin-phycoerythrin. Median fluorescence intensity (MFI) was acquired on a Luminex INTELLIFLEX platform. Duplicate measurements with coefficients of variation greater than 20% were repeated (\u003Cem\u003EAyouba JCM 2016, Berry BioRxiv 2026\u003C\/em\u003E).\u003Csup\u003E\u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E\u003C\/sup\u003E The median of the duplicates per sample was used in the statistical analysis. Antibody responses were analysed descriptively across vaccine groups, age strata and timepoints.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-7\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EResults\u003C\/h2\u003E\u003Cp id=\u0022p-26\u0022\u003EA total of 179 serum samples from vaccinated participants enrolled in the PREVAC trial were included. Samples were collected at D28 (n=55, 30.7%) and M3 (n=124, 69.3%) following vaccination. Participants received the heterologous Ad26\/MVA regimen (72 samples, 40.2%), a single-dose rVSV vaccine (72 samples, 40.2%), or a rVSV booster strategy (35 samples, 19.6%). Adults (n=108, 60.3%) and children (n=71, 39.7%) samples from multiple PREVAC study sites in West Africa (\u003Ca id=\u0022xref-table-wrap-1-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E) were included. Overall, participant samples reflect the multicentre and age-diverse PREVAC trial population\u003Csup\u003E\u003Ca id=\u0022xref-ref-8-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E\u003C\/sup\u003E enabling exploratory comparisons across vaccine platforms, age strata, and timepoints.\u003C\/p\u003E\u003Cp id=\u0022p-27\u0022\u003ECross-reactive antibody responses against EBOV (KIK and MAY strains) and BDBV were detected across all vaccine strategies and timepoints at both D28 and M3 (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E, Figure S1) while responses against Marburg were below the limit of detection. This pattern was consistent across adults and children and showed heterologous humoral immunity against BDBV following EBOV vaccination with either the rVSV vaccine or the Ad26.ZEBOV\/MVA-BN-Filo vaccine (\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E, \u003Ca id=\u0022xref-fig-1-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E). BDBV-specific responses were consistently lower than homologous EBOV responses across all vaccine regimens and timepoints. In rVSV recipients, median responses against BDBV were 282 (IQR 164\u2013644) at D28 and 130 (106\u2013436) at M3, compared with 1788 (832\u20133311) and 1069 (747\u20131876) against EBOV Kikwit, respectively. Similar findings were observed in the rVSV booster group (BDBV: 236 [114\u2013865] at D28 and 246 [137\u2013553] at M3), remaining substantially lower than homologous Kikwit responses.\u003C\/p\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/1226829\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/1226829\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/1226829\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EDescription of the antibody response at Day 28 and Month 3 post-vaccination by rVSV, rVSV-rVSV and Ad26\/MVA respectively.\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2026\/05\/28\/2026.05.27.26354223\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Description of the binding antibody response measured by multiplex Luminex (net MFI) at day 28 and Month 3 after rVSV, rVSV booster and Ad26 \/ MVA vaccination, respectively \u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-822227248\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;span xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot; class=\u0026quot;caption-title\u0026quot;\u0026gt;Description of the binding antibody response measured by multiplex Luminex (net MFI) at day 28 and Month 3 after rVSV, rVSV booster and Ad26 \/ MVA vaccination, respectively\u0026lt;\/span\u0026gt; \u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 1.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2026\/05\/28\/2026.05.27.26354223\/F1.medium.gif\u0022 width=\u0022365\u0022 height=\u0022440\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2026\/05\/28\/2026.05.27.26354223\/F1.medium.gif\u0022 width=\u0022365\u0022 height=\u0022440\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2026\/05\/28\/2026.05.27.26354223\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2026\/05\/28\/2026.05.27.26354223\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EDescription of the binding antibody response measured by multiplex Luminex (net MFI) at day 28 and Month 3 after rVSV, rVSV booster and Ad26 \/ MVA vaccination, respectively\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-28\u0022\u003EFollowing the heterologous Ad26.ZEBOV\/MVA-BN-Filo regimen, BDBV responses were higher at M3 (median MFI 433 (236\u2013994)) than at D28 (median MFI 83 (44\u2013131)), but remained markedly lower than corresponding EBOV Kikwit responses. These findings show that current licensed EBOV vaccines induced limited but measurable heterologous humoral responses against BDBV.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-8\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EDiscussion\u003C\/h2\u003E\u003Cp id=\u0022p-29\u0022\u003EThe ongoing BDBV outbreak in the DRC and Uganda is occurring in a context of extreme vulnerability, with no licensed vaccines or therapeutics specifically available for this ebolavirus species. Therefore, evidence supporting the ability of existing vaccines developed against Zaire EBOV to induce a humoral response and a degree of cross-protective immunity for BDBV is of immediate public health relevance.\u003C\/p\u003E\u003Cp id=\u0022p-30\u0022\u003EIn this analysis, we showed that both licensed EBOV vaccines induced detectable cross-reactive binding antibody responses against BDBV glycoprotein. These responses were observed across vaccine platforms, age groups, and timepoints, indicating heterologous humoral recognition following EBOV-based vaccination. Responses to BDBV were consistently and substantially lower than those against homologous EBOV glycoproteins (Kikwit and Mayinga), indicating limited quantitative cross-reactivity, but were markedly higher than responses against Marburg virus GP. We did not find a meaningful increase in BDBV responses following the homologous rVSV boost consistent with prior findings for homologous EBOV responses in PREVAC trial.\u003Csup\u003E\u003Ca id=\u0022xref-ref-8-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E\u003C\/sup\u003E These observations align with non-human primate data showing partial and incomplete protection against BDBV following rVSV-based vaccination.\u003Csup\u003E\u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E\u003C\/sup\u003E By contrast, the heterologous Ad26.ZEBOV\/MVA-BN-Filo regimen showed a progressive increase in BDBV-specific antibodies between day 28 and month 3, suggesting delayed maturation of cross-reactive humoral responses.\u003C\/p\u003E\u003Cp id=\u0022p-31\u0022\u003EOf note, the absence of a validated immunological correlate of protection or a minimal threshold of protection for anti-EBOV GP IgG antibodies may limit the interpretation of these results. However, EBOV GP-binding antibodies have been widely used as immunological readouts in vaccine studies and these measures have previously shown associations with vaccine-induced protection in EBOV studies\u003Csup\u003E\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E\u003C\/sup\u003E supporting their use as biological relevant measures in the present study. Moreover, the Luminex platform used here has previously demonstrated concordance with the reference FANG ELISA assay.\u003Csup\u003E\u003Ca id=\u0022xref-ref-11-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E\u003C\/sup\u003E\u003C\/p\u003E\u003Cp id=\u0022p-32\u0022\u003ESeveral limitations warrant consideration. This exploratory analysis was performed on a subset of available PREVAC samples rather than on the full trial population. Only binding antibody responses were assessed, without measurement of neutralisation or cellular immunity. Finally, antigenic differences between the 2007 Uganda BDBV variant used in this study and viruses circulating in the current outbreak may limit direct extrapolation. However, this limitation could be applied also when licensed vaccines (including the older EBOV variants Mayinga and Kikwit) are deployed during recent EBOV outbreaks.\u003C\/p\u003E\u003Cp id=\u0022p-33\u0022\u003EAlthough no direct assessment of vaccine efficacy against BDBV infection or disease can be made, in the context of an unfolding outbreak and the absence of BDBV-specific medical countermeasures, these data provide biological support for the the plausibility of partial heterologous immunity against BDBV following EBOV vaccination.\u003C\/p\u003E\u003Cp id=\u0022p-34\u0022\u003EIn the absence of approved BDBV-specific vaccines or therapeutics, currently licensed EBOV vaccines remain among the only immediately deployable vaccine platforms available in affected regions. Importantly, the markedly reduced magnitude of BDBV responses related to homologous EBOV responses underscores the uncertainty regarding the level and durability of potential clinical protection. These findings highlight the urgent need for prospective clinical evaluation of currently available Ebola vaccines during BDBV outbreaks, including assessment of protection against infection and disease severity. More broadly, they reinforce the necessity of accelerating development of broadly protective or multivalent pan-filovirus vaccine strategies capable of spanning genetically diverse ebolavirus species.\u003C\/p\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ENotes\u003C\/h3\u003E\u003Cp id=\u0022p-35\u0022\u003EThe members of the writing committee assume responsibility for the overall content and integrity of this article.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-10\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ETrial registration numbers\u003C\/h3\u003E\u003Cp id=\u0022p-36\u0022\u003E\u003Ca href=\u0022https:\/\/clinicaltrials.gov\/\u0022\u003EClinicalTrials.gov\u003C\/a\u003E number, \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT02876328\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2026%2F05%2F28%2F2026.05.27.26354223.atom\u0022\u003ENCT02876328\u003C\/a\u003E \u003Ca href=\u0022https:\/\/clinicaltrials.gov\/study\/NCT02876328\u0022\u003Ehttps:\/\/clinicaltrials.gov\/study\/NCT02876328\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-37\u0022\u003EEudraCT number 2017-001798-18 \u003Ca href=\u0022https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001798-18\/3rd\u0022\u003Ehttps:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001798-18\/3rd\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-38\u0022\u003EPan African Clinical Trials Registry number, PACTR201712002760250.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-11\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EOpen Science\u003C\/h3\u003E\u003Cp id=\u0022p-39\u0022\u003EPREVAC pseudonymized data are sensitive data collected through a clinical trial. Therefore, for participants data protection and privacy, legal and ethical reasons, the PREVAC pseudonymized data cannot be shared publicly.\u003C\/p\u003E\u003Cp id=\u0022p-40\u0022\u003EThe PREVAC metadata are available on the Recherche Data Gouv repository, DOI: 10.57745\/PVXRMC (\u003Ca href=\u0022https:\/\/doi.org\/10.57745\/PVXRMC\u0022\u003Ehttps:\/\/doi.org\/10.57745\/PVXRMC\u003C\/a\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-41\u0022\u003EAuthorization for the use of the PREVAC\/PREVAC-UP pseudonymized clinical and immunological data must be granted by the sponsors and the concerned country PIs. The final decision to either authorize or not the use of the data and data transfer lies with the sponsors in order to ensure the data request is in accordance with legal and ethical regulations. If a data request is granted, a DTA (data transfer agreement) must be established.\u003C\/p\u003E\u003Cp id=\u0022p-42\u0022\u003EFor any additional question regarding access to the PREVAC\/PREVAC UP pseudonymized data please contact: \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Epromoteur.inserm{at}inserm.fr\u003C\/span\u003E\u003C\/span\u003E.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-13\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-43\u0022\u003EPREVAC pseudonymized data are sensitive data collected through a clinical trial. Therefore, for participants data protection and privacy, legal and ethical reasons, the PREVAC pseudonymized data cannot be shared publicly.\nThe PREVAC metadata are available on the Recherche Data Gouv repository, DOI: 10.57745\/PVXRMC (\u003Ca href=\u0022https:\/\/doi.org\/10.57745\/PVXRMC\u0022\u003Ehttps:\/\/doi.org\/10.57745\/PVXRMC\u003C\/a\u003E).\nAuthorization for the use of the PREVAC\/PREVAC-UP pseudonymized clinical and immunological data must be granted by the sponsors and the concerned country PIs. The final decision to either authorize or not the use of the data and data transfer lies with the sponsors in order to ensure the data request is in accordance with legal and ethical regulations. If a data request is granted, a DTA (data transfer agreement) must be established.\nFor any additional question regarding access to the PREVAC\/PREVAC UP pseudonymized data please contact: \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Epromoteur.inserm{at}inserm.fr\u003C\/span\u003E\u003C\/span\u003E.\n\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-14\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EFunding\u003C\/h2\u003E\u003Cp id=\u0022p-44\u0022\u003EThis research was supported in part by the US National Institutes of Health (NIH), by the French Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (Inserm) and by the London School of Hygiene and Tropical Medicine (LSHTM).\u003C\/p\u003E\u003Cp id=\u0022p-45\u0022\u003EThe clinical trial was conducted with the support of Janssen, Bavarian Nordic and Merck \u0026amp; Co., Inc., Rahway, NJ, USA who provided the vaccines according to the EBOVAC 1 grant agreement.\u003C\/p\u003E\u003Cp id=\u0022p-46\u0022\u003EThis project is part of the EDCTP2 programme supported by the European Union (grant number RIA2017S-2014 \u2013 PREVAC-UP).\u003C\/p\u003E\u003Cp id=\u0022p-47\u0022\u003EThis project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2JU) under grant agreement No 115854, EBOVAC1. This Joint Undertaking receives support from the European Union\u2019s Horizon 2020 research and innovation program and EFPIA.\u003C\/p\u003E\u003Cp id=\u0022p-48\u0022\u003EFunding provided in part by NCI contract HHSN261201500003I and 75N91019D00024 through the Frederick National Laboratory for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention trade names, commercial products, or organizations imply endorsement by the U.S. Government.\u003C\/p\u003E\u003Cp id=\u0022p-49\u0022\u003EThe project has been funded by a dedicated Inserm allocation on behalf of the French Research Ministry.\u003C\/p\u003E\u003Cp id=\u0022p-50\u0022\u003EThe dissemination represents only the authors\u2019 views and IMI2JU is not responsible for any use of the information contained in the dissemination.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ack\u0022 id=\u0022ack-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAcknowledgements\u003C\/h2\u003E\u003Cp id=\u0022p-51\u0022\u003EWe are grateful to the Ministries of Health of Guinea, Liberia, Sierra Leone and Mali who permitted the conduct of the trial. We furthermore thank Alima, GOAL, and all site collaborators for their contribution in the implementation of original PREVAC trial. The authors and study team wish to thank the participants who consented to the trial.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022funding-group\u0022\u003E\u003Ch2\u003EFunder Information Declared\u003C\/h2\u003E\u003Cdiv class=\u0022award-group\u0022 id=\u0022award-group-1\u0022\u003E\u003Cspan class=\u0022funding-source\u0022\u003EEDCTP2\u003C\/span\u003E\u003Cspan class=\u0022award-id\u0022 id=\u0022award-id-1\u0022\u003E, RIA2017S-2014 \u2013 PREVAC-UP\u003C\/span\u003E\u003C\/div\u003E\u003Cdiv class=\u0022award-group\u0022 id=\u0022award-group-2\u0022\u003E\u003Cspan class=\u0022funding-source\u0022\u003EInnovative Medicines Initiative 2 Joint Undertaking\u003C\/span\u003E\u003Cspan class=\u0022award-id\u0022 id=\u0022award-id-2\u0022\u003E, 115854, EBOVAC1\u003C\/span\u003E\u003C\/div\u003E\u003Cdiv class=\u0022award-group\u0022 id=\u0022award-group-3\u0022\u003E\u003Cspan class=\u0022funding-source\u0022\u003ENCI Information Systems (United States), \u003Cspan class=\u0022institution-wrap\u0022\u003E\u003Cspan class=\u0022institution-id\u0022\u003Ehttps:\/\/ror.org\/05mmhfh95\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan class=\u0022award-id\u0022 id=\u0022award-id-3\u0022\u003E, HHSN261201500003I\u003C\/span\u003E\u003Cspan class=\u0022award-id\u0022 id=\u0022award-id-4\u0022\u003E, 75N91019D00024\u003C\/span\u003E\u003C\/div\u003E\u003Cdiv class=\u0022award-group\u0022 id=\u0022award-group-4\u0022\u003E\u003Cspan class=\u0022funding-source\u0022\u003EInserm, \u003Cspan class=\u0022institution-wrap\u0022\u003E\u003Cspan class=\u0022institution-id\u0022\u003Ehttps:\/\/ror.org\/02vjkv261\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section fn-group\u0022 id=\u0022fn-group-1\u0022\u003E\u003Ch2\u003EFootnotes\u003C\/h2\u003E\u003Cul\u003E\u003Cli class=\u0022fn-others\u0022 id=\u0022fn-1\u0022\u003E\u003Cp id=\u0022p-1\u0022\u003E\u003Ca class=\u0022rev-xref\u0022 href=\u0022#xref-fn-1-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cspan class=\u0022fn-label\u0022\u003E*\u003C\/span\u003E A complete list of members of the PREVAC Study Team is provided in the Supplementary\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E1.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 1. in text\u0022 id=\u0022ref-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2026.05.27.26354223v1.1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-source\u0022\u003EMinist\u00e8re de la Sant\u00e9 Publique Hygi\u00e8ne et pr\u00e9voyance sociale\u003C\/span\u003E [Internet]. [cited \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2026 May 25];Available from\u003C\/span\u003E: \u003Ca href=\u0022https:\/\/sante.gouv.cd\/epidemie\/ebola-bundibugyo-2026\u0022\u003Ehttps:\/\/sante.gouv.cd\/epidemie\/ebola-bundibugyo-2026\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E2.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-2-1\u0022 title=\u0022View reference 2. in text\u0022 id=\u0022ref-2\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2026.05.27.26354223v1.2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-source\u0022\u003EEbola disease caused by Bundibugyo virus \u2013 Democratic Republic of the Congo\u003C\/span\u003E [Internet]. [cited \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2026 May 25];Available from\u003C\/span\u003E: \u003Ca href=\u0022https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2026-DON603\u0022\u003Ehttps:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2026-DON603\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E3.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference 3. in text\u0022 id=\u0022ref-3\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2026.05.27.26354223v1.3\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EInitial genomes from May 2026 Bundibugyo Virus Disease Outbreak in the Democratic Republic of the Congo and Uganda - Ebolavirus \/ Bundibugyo ebolavirus\u003C\/span\u003E [Internet]. \u003Cspan class=\u0022cit-source\u0022\u003EVirological\u003C\/span\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2026\u003C\/span\u003E [cited \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2026 May 24\u003C\/span\u003E]; Available from: \u003Ca href=\u0022https:\/\/virological.org\/t\/initial-genomes-from-may-2026-bundibugyo-virus-disease-outbreak-in-the-democratic-republic-of-the-congo-and-uganda\/1032\u0022\u003Ehttps:\/\/virological.org\/t\/initial-genomes-from-may-2026-bundibugyo-virus-disease-outbreak-in-the-democratic-republic-of-the-congo-and-uganda\/1032\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E4.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 4. in text\u0022 id=\u0022ref-4\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2026.05.27.26354223v1.4\u0022 data-doi=\u002210.1038\/s41591-019-0602-4\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEhrhardt\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZehner\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKr\u00e4hling\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EPolyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E10\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1589\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E600\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNat%2BMed%26rft.volume%253D25%26rft.spage%253D1589%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41591-019-0602-4%26rft_id%253Dinfo%253Apmid%252F31591605%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/s41591-019-0602-4\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=31591605\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2026%2F05%2F28%2F2026.05.27.26354223.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E5.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference 5. in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2026.05.27.26354223v1.5\u0022 data-doi=\u002210.1093\/infdis\/jir350\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFalzarano\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFeldmann\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGrolla\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESingle Immunization With a Monovalent Vesicular Stomatitis Virus\u2013Based Vaccine Protects Nonhuman Primates Against Heterologous Challenge With Bundibugyo ebolavirus\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Infect Dis\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E204\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003Esuppl_3\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003ES1082\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ%2BInfect%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1093%252Finfdis%252Fjir350%26rft_id%253Dinfo%253Apmid%252F21987745%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/infdis\/jir350\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=21987745\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2026%2F05%2F28%2F2026.05.27.26354223.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E6.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6. in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2026.05.27.26354223v1.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMire\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGeisbert\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMarzi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAgans\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFeldmann\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGeisbert\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETW\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EVesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLOS Neglected Tropical Diseases\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E12\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003Ee2600\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPLOS%2BNeglected%2BTropical%2BDiseases%26rft.volume%253D7%26rft.spage%253D2600e%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E7.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7. in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2026.05.27.26354223v1.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMdluli\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWollen-Roberts\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMerbah\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EEbola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESci Transl Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2025\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E17\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E792\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003Eeadq2496\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DSci%2BTransl%2BMed%26rft.volume%253D17%26rft.spage%253Deadq2496%26rft_id%253Dinfo%253Apmid%252F40173257%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=40173257\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2026%2F05%2F28%2F2026.05.27.26354223.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E8.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-8-1\u0022 title=\u0022View reference 8. in text\u0022 id=\u0022ref-8\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2026.05.27.26354223v1.8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPREVAC Study\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETeam\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKieh\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERichert\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ERandomized Trial of Vaccines for Zaire Ebola Virus Disease\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E387\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E26\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2411\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E24\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D387%26rft.spage%253D2411%26rft_id%253Dinfo%253Apmid%252F36516078%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=36516078\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2026%2F05%2F28%2F2026.05.27.26354223.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E9.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference 9. in text\u0022 id=\u0022ref-9\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2026.05.27.26354223v1.9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBadio\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELhomme\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKieh\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EPartnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETrials\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E22\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E86\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTrials%26rft.volume%253D22%26rft.spage%253D86%26rft_id%253Dinfo%253Apmid%252F33485369%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=33485369\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2026%2F05%2F28%2F2026.05.27.26354223.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E10.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-10-1\u0022 title=\u0022View reference 10. in text\u0022 id=\u0022ref-10\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2026.05.27.26354223v1.10\u0022 data-doi=\u002210.1128\/JCM.01979-16\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAyouba\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETour\u00e9\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EButel\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EDevelopment of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Microbiol\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E55\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E165\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E76\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ%2BClin%2BMicrobiol%26rft_id%253Dinfo%253Adoi%252F10.1128%252FJCM.01979-16%26rft_id%253Dinfo%253Apmid%252F27795350%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamNtIjtzOjU6InJlc2lkIjtzOjg6IjU1LzEvMTY1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjYvMDUvMjgvMjAyNi4wNS4yNy4yNjM1NDIyMy5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E11.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference 11. in text\u0022 id=\u0022ref-11\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2026.05.27.26354223v1.11\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBerry\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBen Farhat\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECallier\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EComparison of Four Assays That Measure Antibodies to Ebola Virus Glycoprotein\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2026\u003C\/span\u003E;\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E12.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 12. in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2026.05.27.26354223v1.12\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERoozendaal\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHendriks\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003Evan Effelterre\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ENonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003Enpj Vaccines\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E112\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253Dnpj%2BVaccines%26rft.volume%253D5%26rft.spage%253D112%26rft_id%253Dinfo%253Apmid%252F33335092%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=33335092\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2026%2F05%2F28%2F2026.05.27.26354223.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E13.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2026.05.27.26354223v1.13\u0022 data-doi=\u002210.1038\/nrmicro2129\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESullivan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMartin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGraham\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENabel\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGJ\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ECorrelates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Rev Microbiol\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E393\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E400\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNature%2Breviews.%2BMicrobiology%26rft.stitle%253DNat%2BRev%2BMicrobiol%26rft.aulast%253DSullivan%26rft.auinit1%253DN.%2BJ.%26rft.volume%253D7%26rft.issue%253D5%26rft.spage%253D393%26rft.epage%253D400%26rft.atitle%253DCorrelates%2Bof%2Bprotective%2Bimmunity%2Bfor%2BEbola%2Bvaccines%253A%2Bimplications%2Bfor%2Bregulatory%2Bapproval%2Bby%2Bthe%2Banimal%2Brule.%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnrmicro2129%26rft_id%253Dinfo%253Apmid%252F19369954%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/nrmicro2129\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=19369954\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2026%2F05%2F28%2F2026.05.27.26354223.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000265783400015\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E14.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference 14. in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2026.05.27.26354223v1.14\u0022 data-doi=\u002210.1126\/scitranslmed.3004582\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWong\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERichardson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPillet\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EImmune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EScience Translational Medicine\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E158\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E158ra146\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E158ra146\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DScience%2BTranslational%2BMedicine%26rft.stitle%253DSci%2BTransl%2BMed%26rft.aulast%253DWong%26rft.auinit1%253DG.%26rft.volume%253D4%26rft.issue%253D158%26rft.spage%253D158ra146%26rft.epage%253D158ra146%26rft.atitle%253DImmune%2BParameters%2BCorrelate%2Bwith%2BProtection%2BAgainst%2BEbola%2BVirus%2BInfection%2Bin%2BRodents%2Band%2BNonhuman%2BPrimates%26rft_id%253Dinfo%253Adoi%252F10.1126%252Fscitranslmed.3004582%26rft_id%253Dinfo%253Apmid%252F23115355%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6InNjaXRyYW5zbWVkIjtzOjU6InJlc2lkIjtzOjE0OiI0LzE1OC8xNThyYTE0NiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI2LzA1LzI4LzIwMjYuMDUuMjcuMjYzNTQyMjMuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_zP7WWIfzbyzvaM63L39cNV2juU_1XVH7wduFK9gcMNI.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}